CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of CryoPort, Inc. (NASDAQ:CYRX) have received an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $12.5556.

A number of analysts recently commented on CYRX shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research report on Saturday, September 27th. KeyCorp upgraded CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 target price for the company in a research note on Wednesday, August 6th. Leerink Partnrs raised CryoPort from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 6th. Stephens assumed coverage on CryoPort in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 target price for the company. Finally, Leerink Partners raised CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price target for the company in a report on Wednesday, August 6th.

CryoPort Stock Up 3.4%

CYRX opened at $9.68 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. The business has a 50 day simple moving average of $8.83 and a 200-day simple moving average of $7.28. The stock has a market capitalization of $484.68 million, a P/E ratio of 7.28 and a beta of 1.61. CryoPort has a 12 month low of $4.58 and a 12 month high of $10.46.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The business had revenue of $45.45 million during the quarter, compared to analyst estimates of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that CryoPort will post -0.99 earnings per share for the current fiscal year.

Insider Transactions at CryoPort

In other news, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the sale, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This represents a 4.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ramkumar Mandalam sold 40,728 shares of the firm’s stock in a transaction that occurred on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the completion of the sale, the director owned 92,328 shares in the company, valued at approximately $668,454.72. This represents a 30.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 80,028 shares of company stock worth $661,252. 10.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CryoPort

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its position in shares of CryoPort by 23.8% during the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company’s stock valued at $476,000 after purchasing an additional 15,036 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of CryoPort by 154.5% during the 1st quarter. Russell Investments Group Ltd. now owns 32,761 shares of the company’s stock worth $199,000 after acquiring an additional 19,886 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of CryoPort during the 4th quarter worth $95,000. CWM LLC boosted its stake in shares of CryoPort by 1,437.0% during the 1st quarter. CWM LLC now owns 11,328 shares of the company’s stock worth $69,000 after acquiring an additional 10,591 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of CryoPort by 7.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company’s stock worth $8,135,000 after acquiring an additional 73,949 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.